Desloratadine Teva

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
09-06-2022
产品特点 产品特点 (SPC)
09-06-2022
公众评估报告 公众评估报告 (PAR)
08-12-2011

有效成分:

desloratadine

可用日期:

Teva B.V

ATC代码:

R06AX27

INN(国际名称):

desloratadine

治疗组:

Antihistamines for systemic use,

治疗领域:

Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal

疗效迹象:

Desloratadine Teva is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.

產品總結:

Revision: 18

授权状态:

Authorised

授权日期:

2011-11-24

资料单张

                                17
B. PACKAGE LEAFLET
18
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DESLORATADINE TEVA 5 MG FILM-COATED TABLETS
Desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Desloratadine Teva is and what it is used for
2.
What you need to know before you take Desloratadine Teva
3.
How to take Desloratadine Teva
4.
Possible side effects
5.
How to store Desloratadine Teva
6.
Contents of the pack and other information
1.
WHAT DESLORATADINE TEVA IS AND WHAT IT IS USED FOR
WHAT DESLORATADINE TEVA IS
Desloratadine Teva contains desloratadine which is an antihistamine.
HOW DESLORATADINE TEVA WORKS
Desloratadine Teva is an antiallergy medicine that does not make you
drowsy. It helps control your allergic
reaction and its symptoms.
WHEN DESLORATADINE TEVA SHOULD BE USED
Desloratadine Teva relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages
caused by an allergy, for example, hay fever or allergy to dust mites)
in adults and adolescents 12 years of
age and older. These symptoms include sneezing, runny or itchy nose,
itchy palate, and itchy, red or watery
eyes.
Desloratadine Teva is also used to relieve the symptoms associated
with urticaria (a skin condition caused by
an allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DESLORATADINE TEVA
DO NOT TAKE DESLORATADINE TEVA
•
if you are allergic to desloratadine, or any of
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Desloratadine Teva 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect:
Each film-coated tablet contains 1.2 mg of lactose monohydrate (see
section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Blue, round, biconvex film-coated tablet, plain on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Desloratadine Teva is indicated in adults and adolescents aged 12
years and older for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ _
_Adults and adolescents (12 years of age and over) _
The recommended dose of Desloratadine Teva 5 mg film-coated tablets is
one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than 4 weeks)
should be managed in accordance with the evaluation of patient’s
disease history and the treatment could be
discontinued after symptoms are resolved and reinitiated upon their
reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than 4 weeks),
continued treatment may be proposed to the patients during the
allergen exposure periods.
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents 12 through
17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Desloratadine Teva 5 mg film-coated tablets
in children below the age of 12 years
have not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
4.3
CONTRAINDICATIONS
3
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
In the case of severe renal insufficiency, Deslorata
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 09-06-2022
产品特点 产品特点 保加利亚文 09-06-2022
公众评估报告 公众评估报告 保加利亚文 08-12-2011
资料单张 资料单张 西班牙文 09-06-2022
产品特点 产品特点 西班牙文 09-06-2022
公众评估报告 公众评估报告 西班牙文 08-12-2011
资料单张 资料单张 捷克文 09-06-2022
产品特点 产品特点 捷克文 09-06-2022
公众评估报告 公众评估报告 捷克文 08-12-2011
资料单张 资料单张 丹麦文 09-06-2022
产品特点 产品特点 丹麦文 09-06-2022
公众评估报告 公众评估报告 丹麦文 08-12-2011
资料单张 资料单张 德文 09-06-2022
产品特点 产品特点 德文 09-06-2022
公众评估报告 公众评估报告 德文 08-12-2011
资料单张 资料单张 爱沙尼亚文 09-06-2022
产品特点 产品特点 爱沙尼亚文 09-06-2022
公众评估报告 公众评估报告 爱沙尼亚文 08-12-2011
资料单张 资料单张 希腊文 09-06-2022
产品特点 产品特点 希腊文 09-06-2022
公众评估报告 公众评估报告 希腊文 08-12-2011
资料单张 资料单张 法文 09-06-2022
产品特点 产品特点 法文 09-06-2022
公众评估报告 公众评估报告 法文 08-12-2011
资料单张 资料单张 意大利文 09-06-2022
产品特点 产品特点 意大利文 09-06-2022
公众评估报告 公众评估报告 意大利文 08-12-2011
资料单张 资料单张 拉脱维亚文 09-06-2022
产品特点 产品特点 拉脱维亚文 09-06-2022
公众评估报告 公众评估报告 拉脱维亚文 08-12-2011
资料单张 资料单张 立陶宛文 09-06-2022
产品特点 产品特点 立陶宛文 09-06-2022
公众评估报告 公众评估报告 立陶宛文 08-12-2011
资料单张 资料单张 匈牙利文 09-06-2022
产品特点 产品特点 匈牙利文 09-06-2022
公众评估报告 公众评估报告 匈牙利文 08-12-2011
资料单张 资料单张 马耳他文 09-06-2022
产品特点 产品特点 马耳他文 09-06-2022
公众评估报告 公众评估报告 马耳他文 08-12-2011
资料单张 资料单张 荷兰文 09-06-2022
产品特点 产品特点 荷兰文 09-06-2022
公众评估报告 公众评估报告 荷兰文 08-12-2011
资料单张 资料单张 波兰文 09-06-2022
产品特点 产品特点 波兰文 09-06-2022
公众评估报告 公众评估报告 波兰文 08-12-2011
资料单张 资料单张 葡萄牙文 09-06-2022
产品特点 产品特点 葡萄牙文 09-06-2022
公众评估报告 公众评估报告 葡萄牙文 08-12-2011
资料单张 资料单张 罗马尼亚文 09-06-2022
产品特点 产品特点 罗马尼亚文 09-06-2022
公众评估报告 公众评估报告 罗马尼亚文 08-12-2011
资料单张 资料单张 斯洛伐克文 09-06-2022
产品特点 产品特点 斯洛伐克文 09-06-2022
公众评估报告 公众评估报告 斯洛伐克文 08-12-2011
资料单张 资料单张 斯洛文尼亚文 09-06-2022
产品特点 产品特点 斯洛文尼亚文 09-06-2022
公众评估报告 公众评估报告 斯洛文尼亚文 08-12-2011
资料单张 资料单张 芬兰文 09-06-2022
产品特点 产品特点 芬兰文 09-06-2022
公众评估报告 公众评估报告 芬兰文 08-12-2011
资料单张 资料单张 瑞典文 09-06-2022
产品特点 产品特点 瑞典文 09-06-2022
公众评估报告 公众评估报告 瑞典文 08-12-2011
资料单张 资料单张 挪威文 09-06-2022
产品特点 产品特点 挪威文 09-06-2022
资料单张 资料单张 冰岛文 09-06-2022
产品特点 产品特点 冰岛文 09-06-2022
资料单张 资料单张 克罗地亚文 09-06-2022
产品特点 产品特点 克罗地亚文 09-06-2022

搜索与此产品相关的警报